Market Overview:
The global Newcastle disease treatment market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of Newcastle disease, rising demand for poultry meat and eggs, and technological advancements in the vaccine industry. By type, the live attenuated vaccine segment is expected to dominate the market during the forecast period owing to its high efficacy and safety as compared to other types of vaccines. By application, veterinary hospitals are expected to account for a major share of the market during the forecast period owing to their large customer base and widespread presence across regions. North America is estimatedto bethe largest regional market for Newcastle disease treatment in 2018 followed by Europeand Asia Pacific respectively.
Product Definition:
Newcastle Disease Treatment is a vaccine that is used to prevent Newcastle disease in poultry. Newcastle disease is a highly contagious viral disease that can cause serious illness or death in poultry. The vaccine helps protect chickens from the virus and helps to prevent the spread of the disease.
Live Attenuated Vaccine:
Live Attenuated Vaccine (LAV) is a vaccine that involves the use of weakened or attenuated bacteria, which are present in an active form inside the animal cells. The vaccine stimulates the body's immune system to produce antibodies against the live bacterial strain.
The process works by creating an immune response against a specific protein found on the surface of certain bacteria, called endotoxin.
Inactivated Vaccine:
Inactivated Vaccine (IV) is a live attenuated vaccine that provides protection against Newcastle disease. It works by stimulating the body's immune system to produce antibodies against the disease causing agent. The vaccine was first approved in Australia for use in humans and has been used on a wide scale since then with success.
Application Insights:
The pet industry is one of the major application areas for Newcastle disease treatment. The rising number of pets and increasing cases of pet diseases have created a significant demand for these products in this sector. In addition, growing awareness among consumers about vaccination against several diseases in animals has increased the sales significantly across veterinary clinics and pharmacies.
The others segment includes military institutes, research laboratories, biotechnology companies and other non-clinical industries that develop vaccines for humans or animals. These companies are involved in the development of new drugs or vaccines to prevent Newcastle disease as well as other livestock diseases such as Foot & Mouth Disease (FMD). Thus, they also purchase these products from manufacturers to test them before mass production begins. This is expected to drive growth over the forecast period due to high demand from various sectors including human medicine and animal health care providers globally which will eventually fuel market growth during future years of analysis (2030 - 2036).
Regional Analysis:
North America held the largest share of over 40.0% in 2017. The disease is highly prevalent in North America, which can be attributed to the presence of a large number of animal population and high veterinary healthcare expenditure in this region. Moreover, increasing R&D investment by major companies for developing novel Newcastle Disease vaccines is also expected to drive the market for newND treatment products during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising awareness about vaccination programs among pet owners and increasing investments by global players for commercialization of their product at affordable prices coupled with growing demand from countries such as China, India, South Korea & Japan that account for majority share regarding prevalence rate & economic performance thereby making it one of most important markets globallyNewcastle Disease Treatment Market Share By Region (Region I includes countries such as Brazil.
Growth Factors:
- Increasing awareness about Newcastle disease and its treatment options among people.
- Growing number of research and development activities for new drugs and therapies for Newcastle disease treatment.
- Rising demand for better healthcare facilities and services across the globe.
- Technological advancements in the field of diagnostics and therapeutics for Newcastle disease treatment market growth drivers 5 Increased funding from government bodies, private organizations, and pharmaceutical companies to support research activities in this domain
Scope Of The Report
Report Attributes
Report Details
Report Title
Newcastle Disease Treatment Market Research Report
By Type
Live Attenuated Vaccine, Inactivated Vaccine, Conjugated Vaccine
By Application
Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes, Retail Pharmacies, Others
By Companies
Indovax, Zoetis, Eli Lilly, Merck, Ceva
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
162
Number of Tables & Figures
114
Customization Available
Yes, the report can be customized as per your need.
Global Newcastle Disease Treatment Market Report Segments:
The global Newcastle Disease Treatment market is segmented on the basis of:
Types
Live Attenuated Vaccine, Inactivated Vaccine, Conjugated Vaccine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes, Retail Pharmacies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Indovax
- Zoetis
- Eli Lilly
- Merck
- Ceva
Highlights of The Newcastle Disease Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Live Attenuated Vaccine
- Inactivated Vaccine
- Conjugated Vaccine
- By Application:
- Veterinary Hospitals
- Veterinary Clinics
- Veterinary Research Institutes
- Retail Pharmacies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Newcastle Disease Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no specific treatment for Newcastle disease, but the patient may need to take antibiotics to prevent infection. In some cases, surgery may be necessary to remove the infected area of the body.
Some of the major companies in the newcastle disease treatment market are Indovax, Zoetis, Eli Lilly, Merck, Ceva.
The newcastle disease treatment market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Newcastle Disease Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Newcastle Disease Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Newcastle Disease Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Newcastle Disease Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Newcastle Disease Treatment Market Size & Forecast, 2020-2028
4.5.1 Newcastle Disease Treatment Market Size and Y-o-Y Growth
4.5.2 Newcastle Disease Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Live Attenuated Vaccine
5.2.2 Inactivated Vaccine
5.2.3 Conjugated Vaccine
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Veterinary Hospitals
6.2.2 Veterinary Clinics
6.2.3 Veterinary Research Institutes
6.2.4 Retail Pharmacies
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Newcastle Disease Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Newcastle Disease Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Live Attenuated Vaccine
9.6.2 Inactivated Vaccine
9.6.3 Conjugated Vaccine
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Veterinary Hospitals
9.10.2 Veterinary Clinics
9.10.3 Veterinary Research Institutes
9.10.4 Retail Pharmacies
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Live Attenuated Vaccine
10.6.2 Inactivated Vaccine
10.6.3 Conjugated Vaccine
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Veterinary Hospitals
10.10.2 Veterinary Clinics
10.10.3 Veterinary Research Institutes
10.10.4 Retail Pharmacies
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Live Attenuated Vaccine
11.6.2 Inactivated Vaccine
11.6.3 Conjugated Vaccine
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Veterinary Hospitals
11.10.2 Veterinary Clinics
11.10.3 Veterinary Research Institutes
11.10.4 Retail Pharmacies
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Live Attenuated Vaccine
12.6.2 Inactivated Vaccine
12.6.3 Conjugated Vaccine
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Veterinary Hospitals
12.10.2 Veterinary Clinics
12.10.3 Veterinary Research Institutes
12.10.4 Retail Pharmacies
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Live Attenuated Vaccine
13.6.2 Inactivated Vaccine
13.6.3 Conjugated Vaccine
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Veterinary Hospitals
13.10.2 Veterinary Clinics
13.10.3 Veterinary Research Institutes
13.10.4 Retail Pharmacies
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Newcastle Disease Treatment Market: Competitive Dashboard
14.2 Global Newcastle Disease Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Indovax
14.3.2 Zoetis
14.3.3 Eli Lilly
14.3.4 Merck
14.3.5 Ceva
